{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.9","upperLimit":"23.1","value":"4.20"},{"groupId":"OG001","lowerLimit":"4.0","upperLimit":"13.0","value":"4.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Time to response (for responders only, per IMWG Uniform Response Criteria) is calculated as the time from the first date of dosing of study medication to the first date of documented response (PR or better).","dispersionType":"Full Range","groups":[{"description":"High risk, transplant non-eligible \\[TNE\\], newly diagnosed multiple myeloma (NDMM) participants who were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \\[CrCl\\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG000","title":"Cohort A: High Risk, TNE"},{"description":"\\>= 65 years old, transplant non-eligible \\[TNE\\], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \\[CrCl\\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles.","id":"OG001","title":"Cohort B: >=65 Years Old, TNE"},{"description":"High risk, post-transplant NDMM participants were administered the following as maintenance therapy: • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle.","id":"OG002","title":"Cohort C: High Risk, Post-transplant"}],"paramType":"MEDIAN","populationDescription":"Efficacy Evaluable Population: Participants in Cohorts A + B who had a response","reportingStatus":"POSTED","timeFrame":"Day 1 of each cycle starting with Cycle 2 up to Cycle 17 plus one week for the end of treatment visit (Day 29 up to Week 73)","title":"Time to Response (for Cohorts A and B)","type":"SECONDARY","unitOfMeasure":"weeks"}